The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Fifty‐ two—Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone
Abstract
ABSTRACT: Men with the metabolic syndrome (MetS) and type 2 diabetes (T2D) often have low testosterone levels. Elevating low testosterone levels may improve features of the MetS and glycemic control. In a single blind, 52‐week randomized clinical trial, the effects of supervised diet and exercise (D&E) with or without transdermal testosterone administration on components of the MetS in hypogonadal men with the MetS and newly diagnosed T2D were assessed. A total of 32 hypogonadal men (total testosterone <12.0 nmol/L) with newly diagnosed T2D and with the MetS as defined by the Adult Treatment Panel III and the International Diabetes Federation received supervised D&E, but 16 received it in combination with testosterone gel (50 mg) once daily (n = 16). No glucose‐lowering agents were administered prior to or during the study period. Outcome measures were components of the MetS as defined by the Adult Treatment Panel III and the International Diabetes Federation. Serum testosterone, glycosylated hemoglobin (HbA 1c), fasting plasma glucose, high‐density lipoprotein cholesterol, triglyceride concentrations, and the waist circumference improved in both treatment groups after 52 weeks of treatment. Addition of testosterone significantly further improved these measures compared with D&E alone. All D&E plus testosterone patients reached the HbA 1c goal of less than 7.0%; 87.5% of them reached an HbA 1c of less than 6.5%. Based on Adult Treatment Panel III guidelines, 81.3% of the patients randomized to D&E plus testosterone no longer matched the criteria of the MetS, whereas 31.3% of the D&E alone participants did. Additionally, testosterone treatment improved insulin sensitivity, adiponectin, and high‐sensitivity C‐reactive protein. Addition of testosterone to supervised D&E results in greater therapeutic improvements of glycemic control and reverses the MetS after 52 weeks of treatment in hypogonadal patients with the MetS and newly diagnosed T2D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While a small, uncontrolled study found that testosterone treatment augmented the reductions in central adiposity and insulin resistance achieved with lifestyle;118”
From Lowered testosterone in male obesity: Mechanisms, morbidity and management (2014) · cites this paper as [118]
In the citing paper
“The addition of testosterone gel to the lifestyle changes resulted in greater improvements of glycemic control and insulin sensitivity [22].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [22]
In the citing paper
“Heufelder et al. found that a lifestyle intervention (supervised diet and exercise) during 52 weeks significantly improved testosterone concentrations and glycemic control in 16 hypogonadal men with metabolic syndrome and newly diagnosed type 2 diabetes.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [22]
In the citing paper
“Heufelder et al. found that a lifestyle intervention (supervised diet and exercise) during 52 weeks significantly improved testosterone concentrations and glycemic control in 16 hypogonadal men with metabolic syndrome and newly diagnosed type 2 diabetes.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [22]
In the citing paper
“Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3–12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“An increase was found to occur after 3 months increasing further during 12 months (43), after 6 months, (35) or close to 1 year (44). Continuous increase was observed over 24 months (32).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“A decline in HbA1c was observed after 3 months (31, 36, 43) with further decrease after 12 months (43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“Several studies indicate that upon testosterone administration, serum glucose is reduced after 3 months in men with impaired glucose tolerance (31, 36, 43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“A decrease in serum proinsulin and insulin was noted after 3 months (43) or 6 months (45), and a decrease in homeostasis model assessment index of insulin resistance (HOMA-IR) after 3 months (36) or 6 months (45–47).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“A decrease in C-reactive protein (CRP) was observed after 3 weeks (63) and in other studies after 3 months (32, 43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“Other studies have found a rise of PSA levels after 3 months (40), some only after 12 months (43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“Only few studies to date reported that combination of TRT and LSM is superior to LSM alone in increasing insulin sensitivity, glycemic control, muscle mass and reducing liver fat (4, 5).”
From Effects of liraglutide on obesity-associated functional hypogonadism in men (2019) · cites this paper as [4]
In the citing paper
“A compelling number of clinical studies demonstrated that TRT led to improvement in glycemic control and insulin sensitivity (4, 5, 37, 42), whereas some failed to confirm these observations (43).”
From Effects of liraglutide on obesity-associated functional hypogonadism in men (2019) · cites this paper as [4]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program
Lévy, J., Matthews, D. R., & Hermans, M. P. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2191 · Cited by 2,023
Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2006) · JAMA · doi:10.1001/jama.295.11.1288 · Cited by 1,354
Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791
The Metabolic Syndrome: Inflammation, Diabetes Mellitus, and Cardiovascular Disease
Haffner, S. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.010 · Cited by 568
Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men
Pitteloud, N., Mootha, V. K., Dwyer, A. A., Hardin, M., Lee, H., Eriksson, K.-F., Tripathy, D., Yialamas, M., Groop, L., Elahi, D., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1636 · Cited by 472
Endogenous sex hormones and metabolic syndrome in aging men
Muller, M., Grobbee, D. E., den Tonkelaar, I., Lamberts, S. W. J., & van der Schouw, Y. T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1158 · Cited by 456
Cited by
Sorted by citations
Items 201–300 of 348
Elsaied, M. A., Masallat, D. T. A., & Abdel‐Hamid, I. A. (2018) · American Journal of Men s Health · doi:10.1177/1557988318807049 · Cited by 14
Does low testosterone affect adaptive properties of adipose tissue in obese men?
Ruige, J. B. (2010) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2010.525239 · Cited by 14
Testosterone, obesity, diabetes and the metabolic syndrome
Jones, T. H., & Channer, K. S. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.012 · Cited by 13
Wen, J., Wen, L., Zhao, Y., Li, Q., Lin, W., Huang, H., Liang, J., Li, L., Lin, L., & Chen, G. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00233 · Cited by 13
Han, T. S., & Lean, M. E. J. (2010) · Medicine · doi:10.1016/j.mpmed.2010.10.010 · Cited by 13
Tratamento medicamentoso da sarcopenia
de Souza, C. G. (2020) · Revista Brasileira de Ortopedia · doi:10.1055/s-0040-1709732 · Cited by 19
Hackett, G. I. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02922.x · Cited by 13
Oni, O. A., Sharma, R., Chen, G., Sharma, M., Gupta, K., Dawn, B., Sharma, R., Parashara, D., Savin, V. J., Cherian, G., et al. (2017) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2017.05.003 · Cited by 12
Cardio-oncology in advanced prostate cancer
Chen, K., Wong, T. H., Tan, Y. G., Tay, K. J., Tan, W. C., Chan, J., Ho, H. S. S., Cheng, C. W. S., Teoh, J. Y., Chiu, P. K., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1386597 · Cited by 11
Chillarón, J. J., Fernández-Miró, M., Albareda, M., Fontserè, S., Colom, C., Vila, L. I. S., Pedro‐Botet, J., & Roux, J. A. F. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0195 · Cited by 11
Lu, Y., Li, J., Cheng, X., Li, N., Miao, X., Sun, B., Yan, S., & Li, C. (2018) · The Aging Male · doi:10.1080/13685538.2018.1481940 · Cited by 11
Park, B., & Lee, Y. (2019) · The World Journal of Men s Health · doi:10.5534/wjmh.180103 · Cited by 11
Effect of Testosterone Supplementation on Symptoms in Men with Hypogonadism
Ramasamy, R., Wilken, N., Scovell, J. M., & Lipshultz, L. I. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.048 · Cited by 11
Eshraghi, Y., Hanks, N., Rooney, S., Ata, F. M. Y., Velasco, C., Guirguis, M., & Uwaifo, G. (2021) · Ochsner Journal · doi:10.31486/toj.20.0103 · Cited by 10
Metabolic Syndrome, Obesity Paradox and Testosterone Level
Emanuele, V. (2015) · Endocrinology & Metabolic Syndrome · doi:10.4172/2161-1017.1000172 · Cited by 10
Pasquali, D., Chiodini, P., Simeon, V., Ferlin, A., Vignozzi, L., Corona, G., Lanfranco, F., Rochira, V., Calogero, A. E., Bonomi, M., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01816-4 · Cited by 11
Vincenzo, A. D., Silvestrin, V., Bertoli, E., D, M. F. M., Pagano, C., Fabris, R., Vettor, R., Busetto, L., & Rossato, M. (2018) · The Aging Male · doi:10.1080/13685538.2018.1528445 · Cited by 10
Testosterone Therapy for Prevention and Treatment of Obesity in Men
Caliber, M., & Saad, F. (2020) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0010 · Cited by 11
Self-citationErectile dysfunction and hypogonadism (low testosterone).
Barkin, J. (2011) · PubMed · Cited by 10
Lee, J., Shah, P. H., Uma, D., Salvi, D. J., Rabbani, R., & Hamid, P. (2021) · Cureus · doi:10.7759/cureus.17475 · Cited by 10
Rotter, I., Kosik-Bogacka, D. I., Dołęgowska, B., Skonieczna‐Żydecka, K., Pawlukowska, W., & Laszczyńska, M. (2015) · The Aging Male · doi:10.3109/13685538.2015.1077507 · Cited by 9
Goncharov, N., Katsya, G. V., Gaivoronskaya, L. M., Zoloedov, V. I., Uskov, V. L., & Gooren, L. J. (2012) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2012-0023 · Cited by 10
Self-citationUkkola, O. H., Huttunen, T., Puurunen, V.-P., Piira, O.-P., Niva, J., Lepojärvi, S., Tulppo, M. P., & Huikuri, H. V. (2013) · Annals of Medicine · doi:10.3109/07853890.2012.711951 · Cited by 9
Testosterone Deficiency Associated with Poor Glycemic Control in Korean Male Diabetics
Kim, J., Kim, B. S., Jeon, J. Y., Choi, Y. J., & Chung, Y. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.3.300 · Cited by 9
Hypopituitarism and Cardiovascular Risk
Kraljević, I., Solak, M., Mandić, A., Kozamernik, K. M., Raičević, M., Divanović, A., Kovačević, Z., & Muzurović, E. M. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484251332398 · Cited by 9
Androgen Therapy and Rehospitalization in Older Men With Testosterone Deficiency
Baillargeon, J., Deer, R., Kuo, Y., Zhang, D., Goodwin, J. S., & Volpi, E. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.03.016 · Cited by 8
Azarniad, R., Razi, M., Hasanzadeh, S., & Malekinejad, H. (2020) · Andrologia · doi:10.1111/and.13710 · Cited by 8
The relationship between testosterone and metabolic syndrome
Kawano, H. (2010) · Hypertension Research · doi:10.1038/hr.2010.52 · Cited by 8
A case of Madelung's disease accompanied by Klinefelter's syndrome
Özderya, A., Temizkan, Ş., Tezcan, K. A., Öztürk, F. Y., & Altuntaş, Y. (2015) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-14-0119 · Cited by 8
Testosterone in men's health: a new role for an old hormone
Feeley, R. J., Saad, F., Guay, A. T., & Traish, A. M. (2009) · Journal of Men s Health · doi:10.1016/j.jomh.2009.06.005 · Cited by 8
Self-citationAn Individualized Approach to Managing Testosterone Therapy in the Primary Care Setting
Dobs, A. S., & Campbell, K. J. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s364189 · Cited by 8
Pathophysiology of Type 2 Diabetes
Kesavadev, J., Jawad, F., Deeb, A., Coetzee, A., Ansari, M., Shrestha, D., Somasundaram, N. P., & Kalra, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_9 · Cited by 9
Şimşek, Y., Kaya, M. G., Tanrıverdi, F., Çalapkorur, B., Diri, H., Karaca, Z., Unluhizarci, K., & Keleştimur, F. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0142-1 · Cited by 7
Shaheen, D. (2014) · Advances in Biochemistry · doi:10.11648/j.ab.20140202.12 · Cited by 7
Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism)
Saad, F. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_23 · Cited by 6
Self-citationAntonič, K. G., & Zitzmann, M. (2023) · The Aging Male · doi:10.1080/13685538.2023.2296460 · Cited by 7
Hohl, A., & Ronsoni, M. F. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_15 · Cited by 6
Controversial Effects of Exogenous Testosterone on Cardiovascular Diseases
Al-Khazaali, A., Arora, R. R., & Muttar, S. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000212 · Cited by 6
Management of Hypogonadism in Cardiovascular Patients
Tanna, M. S., Schwartzbard, A. Z., Berger, J. S., Underberg, J. A., Gianos, E., & WEINTRAUB, H. S. (2016) · Urologic Clinics of North America · doi:10.1016/j.ucl.2016.01.011 · Cited by 6
Effects of testosterone replacement on glucose and lipid metabolism
Errazuriz, I., Dube, S., Basu, A., & Basu, R. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000061 · Cited by 6
Ware, W. R. (2010) · Cited by 6
The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems
Antonič, K. G., & Zitzmann, M. (2025) · The Aging Male · doi:10.1080/13685538.2025.2601423 · Cited by 6
Cardiovascular disease and testosterone therapy in male hypogonadism
de Silva, N. L., Grant, B., Minhas, S., & Jayasena, C. N. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15211 · Cited by 6
SECONDARY (ENDOCRINE) HYPERTENSION: LECTURE
Yukina, M. Y., Troshina, E. A., Beltsevich, D. G., & Platonova, N. M. (2016) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2016-44-4-501-512 · Cited by 5
Metabolic syndrome and andrological diseases
Iafrate, M., ERMACORA, C., Morlacco, A., Moro, F. D., Vincenzo, A. D., & Rossato, M. (2022) · Panminerva Medica · doi:10.23736/s0031-0808.22.04628-6 · Cited by 5
New Horizons: Testosterone or Exercise for Cardiometabolic Health in Older Men
GREEN, D. J., Chasland, L. C., Naylor, L. H., & Yeap, B. B. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad175 · Cited by 5
Conners, W. P., & Morgentaler, A. (2013) · Current Urology Reports · doi:10.1007/s11934-013-0370-5 · Cited by 5
Testosterone Replacement Therapy: Who to Evaluate, What to Use, How to Follow, and Who is at Risk?
Afiadata, A., & ELLSWORTH, P. I. (2014) · Hospital Practice · doi:10.3810/hp.2014.12.1160 · Cited by 5
Bajaj, S., Srivastava, A., Varma, A., & Tiwari, A. (2016) · Sri Lanka Journal of Diabetes Endocrinology and Metabolism · doi:10.4038/sjdem.v6i1.7300 · Cited by 5
Quang, L. M., & Kalhan, A. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.192 · Cited by 5
Association between T2DM and the lowering of testosterone levels among Kashmiri males
Farooq, R., Bhat, M. H., Majid, S., & Mir, R. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000288 · Cited by 6
Patients with testosterone deficiency syndrome and type 2 diabetes.
Corona, G., & Maggi, M. (2013) · PubMed · Cited by 4
Benefits of testosterone replacement
Hackett, G. I. (2013) · Trends in Urology & Men s Health · doi:10.1002/tre.342 · Cited by 2
Scherer, T., Metz, M., Beghini, M., Bilban, M., Gensthaler, L., Luca, A. C., Kaplanian, M., Eid, S. A., Koldyka, O., Hackl, M. T., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt7366 · Cited by 5
Tang, X., Xu, Y., Ou, N., Tang, Y., & Chen, H. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf043 · Cited by 4
Debate: Testosterone Therapy Reduces Cardiovascular Risk in Men with Diabetes. Against the Motion
Schooling, C. M., Xu, L., & Zhao, J. V. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0449-2 · Cited by 4
Azad, N., Sakla, N., & Bahn, G. (2018) · Cited by 4
Obesity’s role in secondary male hypogonadism: a review of pathophysiology and management issues
Seyam, O., Gandhi, J., Joshi, G. S., Smith, N. L., & Khan, S. A. (2019) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-019-00056-7 · Cited by 5
Biomarkers of Glucose Homeostasis and Inflammation with Risk of Prostate Cancer: A Case–Cohort Study
Wang, Y., Gapstur, S. M., Newton, C. C., McCullough, M. L., Pollak, M., & Campbell, P. T. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-1060 · Cited by 4
Testosteron und das metabolische Syndrom
Schubert, M., & Jockenhövel, F. (2010) · Der Urologe · doi:10.1007/s00120-009-2198-7 · Cited by 4
The Role of Testosterone Therapy in Cardiovascular Mortality: Culprit or Innocent Bystander?
Tanna, M. S., Schwartzbard, A. Z., Berger, J. S., Alukal, J. P., & WEINTRAUB, H. S. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0490-0 · Cited by 4
Yu, X., Wei, Z., Liu, Y., Zhang, X., & Wang, Q. (2021) · Sexual Medicine · doi:10.1016/j.esxm.2021.100403 · Cited by 4
Tishova, Y. A., & Kalinchenko, S. Y. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000800021 · Cited by 4
Testosterone in men with hypogonadism and high cardiovascular risk, Pros
Rosano, G. M. C., Vitale, C., & Fini, M. (2015) · Endocrine · doi:10.1007/s12020-015-0561-6 · Cited by 4
Androgens and Coronary Artery Disease
Wu, F. C. W., & von Eckardstein, A. (2003) · Humana Press eBooks · doi:10.1385/1-59259-388-7:191 · Cited by 13
Effect of Androgen Deficiency on the Condition of Carbohydrate Metabolism in Men
Mkrtumyan, A. M., Yegshatyan, L. V., & Shishkova, Y. A. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-12-56-66 · Cited by 4
Pathophysiology of Type 2 Diabetes
Kesavadev, J., Jawad, F., Deeb, A., Coetzee, A., Ansari, M., Shrestha, D., Somasundaram, N. P., & Kalra, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_8 · Cited by 3
Relationship of serum testosterone with coronary artery disease in young adult males of Bangladesh
Pramanik, A. K., Bhuiyan, M. M. A., Yesmin, M. S., Ferdousi, S., Parvin, T., Karmoker, K. K., Nahar, S., Goswami, J., & Paul, D. (2022) · Bangabandhu Sheikh Mujib Medical University Journal · doi:10.3329/bsmmuj.v14i3.56601 · Cited by 3
Testostérone plasmatique, obésité, syndrome métabolique et diabète
Prévost, G., Eas, F., & Kuhn, J. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.04.023 · Cited by 3
Screening for Hypogonadism in Primary Healthcare: How to do this Effectively
Livingston, M. A., Jones, R. L., Hackett, G. I., Donnahey, G., Moreno, G., Duff, C. J., & Heald, A. H. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-114866 · Cited by 4
Ho, C., Yu, H., Wang, C., Jaw, F., Hsieh, J., Liao, W.-C., Pu, Y., & Liu, S. (2013) · PLoS ONE · doi:10.1371/annotation/c226aa64-8d3b-4c29-971b-84f87b618291 · Cited by 4
Seasonal Variation in Serum Testosterone Levels: Evidence from 2 Large Institutional Databases
Miller, D., Gurayah, A. A., Weber, A., Schuppe, K. C., Zarli, M., Dullea, A. D., Hwang, K., & Ramasamy, R. (2023) · Urology Research and Practice · doi:10.5152/tud.2023.23077 · Cited by 2
Effects of testosterone deficiency and therapy on the cardiometabolic syndrome in men
Saad, F., & Traish, A. M. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.08.004 · Cited by 2
Self-citationVincenzo, A. D., Russo, L., Doroldi, C. G., Vettor, R., & Rossato, M. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00049 · Cited by 2
Hohl, A., & Ronsoni, M. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_14 · Cited by 2
Unlocking the therapeutic potential and personalized therapy of testosterone: a comprehensive review
Reddy, A. V., Ramasamy, K., Rajendran, P., & Deva, R. (2024) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2024-0035 · Cited by 2
Mel'nichenko, G. A., Shestakova, M. V., Rozhivanov, R. V., Терехова, А. Л., Zilov, A. V., Ladygina, D. O., & Курбатов, Д. Г. (2016) · Diabetes Mellitus · doi:10.14341/7884 · Cited by 2
Luchytskyi, V. Y., Tronko, M. D., & Luchytskyy, Y. V. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.2.2019.166099 · Cited by 2
Androgen Replacement Therapy in Hypogonadal Men
Čeponis, J., Swerdloff, R. S., & Wang, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53298-1_18 · Cited by 2
Benefits and Risks of Testosterone Therapy in Men With Testosterone Deficiency
Traish, A. M., & Morgentaler, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813197-8.00018-x · Cited by 2
Abichandani, V. K., & Kalhan, A. (2023) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_cdrp_20_22 · Cited by 1
The clinical importance of testosterone in men with type 2 diabetes
Hackett, G. I. (2010) · Trends in Urology & Men s Health · doi:10.1002/tre.159 · Cited by 1
Metabolic Syndrome: The Vicious Cycle
Potts, J. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3237-5_8 · Cited by 1
Шарвадзе, Г. Г., Курбатов, Д. Г., Александровна, П. Е., & Мамедов, М. Н. (2010) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2010-6-4-532-538 · Cited by 1
Cardiometabolic effects of testosterone in older men
Hackett, G. I. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000050 · Cited by 1
Uso clínico de esteroides anabolizantes em idosos sarcopênicos
Godoy, I. C., Pontes, L. S., Valentim, T. P., Delbim, L. R., & Martelli, A. (2017) · ARCHIVES OF HEALTH INVESTIGATION · doi:10.21270/archi.v6i2.1791 · Cited by 1
Tiwari, A., & Srivastava, A. (2016) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2016/975 · Cited by 1
Predictive Factors of Efficacy Maintenance after Testosterone Treatment Cessation
Park, M. G., Yeo, J. K., Park, S., Na, W., & Moon, D. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020151 · Cited by 1
Hackett, G. I. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch13 · Cited by 1
Hypogonadism and diabetes mellitus - Implications for cardiovascular risk
Madhu, S. (2017) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-017-0573-2 · Cited by 1
Willemse, P.-P. M., Burggraaf, J., Hamdy, N. A. T., & Osanto, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.567 · Cited by 1
The Plasma Glycome of Women With PCOS is Different From Healthy ControlsPreprint
Holman, M., Li, S. J., Ahern, M. M., Ruhaak, L. R., Karakas, S., & Krishnan, S. (2025) · medRxiv · doi:10.1101/2025.03.14.25323948 · Cited by 1
The Clinical Diagnosis of Androgen Deficiency
Mitchell, G. C., Şerefoğlu, E. C., & Hellstrom, W. J. G. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-179-0_3
Late onset hypogonadism in males - think of it - act on it
Jackson, G. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02865.x
The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes
Quammen, A. (2010) · CommonKnowledge Research Repository (Pacific University Oregon)
García‐Cruz, E., Luqué, P., & Alcaraz, A. (2012) · Revista Internacional de Andrología · doi:10.1016/s1698-031x(12)70043-2
Tishova, Y. A., & Kalinchenko, S. Y. (2009)
Elliott, J. (2016) · uO Research (University of Ottawa) · doi:10.20381/ruor-5176
Fisch, H. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139169349.008
Ho, C. C. K., & Tan, H. M. (2015) · Heart and Metabolism
Metadata
- Authors
- Heufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L.
- Affiliations
- Bayer (Germany) (DE)
- Gulf Medical University (AE)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Gooren, Louis
- Venue
- Journal of Andrology
- Publisher
- Wiley
- Published
- 2009-11-12
- Volume
- 30
- Issue
- 6
- Pages
- 726-733
- ISSN
- 0196-3635 (ISSN-L)
- 1939-4640
- OpenAlex
- W2132592917
- Cited by
- 349
- References
- 26
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 25 · 2021: 19 · 2020: 18 · 2019: 12 · 2018: 19 · 2017: 23 · 2016: 23 · 2015: 29 · 2014: 36 · 2013: 32 · 2012: 23
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Andrology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- transdermal testosterone, hypogonadism, metabolic syndrome, type 2 diabetes, diet and exercise, glycemic control, HbA1c, insulin sensitivity, adiponectin, C-reactive protein, newly diagnosed diabetes, testosterone gel
- MeSH terms
- Administration, Cutaneous, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Insulin Resistance, Cholesterol, HDL, Male, Testosterone, Triglycerides, Exercise, Metabolic Syndrome, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
